Vgard25 mg+2.5 mg+1 mg

Vgard is a combination B-vitamin supplement used for the prevention and treatment of combined deficiency of pyridoxine (vitamin B6), folate/folic acid (vitamin B9), and cobalamin (vitamin B12). Common uses include:

• Established/guideline-supported use: Correction of documented or suspected combined B6, B9, and B12 deficiency due to inadequate dietary intake, malabsorption syndromes, or increased physiological requirement.
• Adjunct use: As an adjunct in individuals with elevated homocysteine levels (hyperhomocysteinemia), often in the context of atherosclerotic vascular disease or peripheral neuropathy; note that evidence for reduction in hard cardiovascular outcomes (heart attack, stroke) from homocysteine-lowering with these vitamins is limited and inconsistent, so this is a supportive rather than a primary therapy.
• Adjunct use: Supportive therapy in nutritional neuropathy and certain megaloblastic anemia presentations where a mixed vitamin deficiency is confirmed, alongside management of the underlying cause.
• General supplementation: For individuals at higher risk of deficiency, such as older adults, people with restrictive diets (e.g., strict vegetarians/vegans for B12), or those with chronic gastrointestinal disease.

Vgard is not a substitute for identifying and treating the underlying cause of a deficiency (e.g., pernicious anemia, malabsorption, or dietary insufficiency), which requires proper medical evaluation.

Each tablet/capsule typically contains a combination of Pyridoxine hydrochloride (Vitamin B6), Folic acid (Vitamin B9), and Cyanocobalamin or Methylcobalamin (Vitamin B12) in varying strengths depending on the formulation and manufacturer.

Vgard is a fixed-dose combination of three water-soluble B-complex vitamins that work together in one-carbon metabolism and red blood cell formation. Pyridoxine (B6) is a cofactor for numerous enzymatic reactions in amino acid and neurotransmitter metabolism; folic acid (B9) is essential for DNA synthesis and cell division; and cobalamin (B12) is required for myelin synthesis and conversion of homocysteine to methionine. Because these three vitamins are metabolically interdependent, they are often combined into a single product for convenience and to support balanced correction of deficiency.

Vgard belongs to the therapeutic class of Vitamin B-complex preparations / hematinics (nutritional supplements).

Vitamin B6, B9 and B12 combines three vitamins with complementary metabolic roles:

• Pyridoxine (Vitamin B6): Converted to pyridoxal-5-phosphate, an essential coenzyme in amino acid metabolism, hemoglobin synthesis, and neurotransmitter (e.g., GABA, serotonin) production.
• Folic acid (Vitamin B9): Reduced to tetrahydrofolate, a coenzyme required for purine and pyrimidine synthesis, and therefore for DNA synthesis and normal red blood cell maturation.
• Cyanocobalamin/Methylcobalamin (Vitamin B12): Acts as a cofactor for methionine synthase (recycling homocysteine to methionine) and for methylmalonyl-CoA mutase, supporting myelin formation and neurological function; also necessary for folate to be used effectively within cells.

Together, these three vitamins lower elevated plasma homocysteine levels and support normal hematologic and neurologic function when deficiency is present.

Take Vgard by mouth, preferably with a meal to minimize gastrointestinal upset. Swallow tablets/capsules whole with a glass of water unless directed otherwise by the product labeling or a physician.

Vgard has the following clinically significant interactions:

• Levodopa (without carbidopa): Pyridoxine (B6) can reduce the effectiveness of levodopa used alone for Parkinson's disease by enhancing its peripheral breakdown; this interaction does not occur with carbidopa-levodopa combinations at standard supplemental B6 doses.
• Phenytoin, phenobarbital, primidone (anticonvulsants): Folic acid (B9) can lower plasma levels of these anticonvulsants, potentially reducing seizure control; monitoring is advised if folic acid is started or stopped in patients on these medicines.
• Methotrexate and other folate antagonists: Folic acid may reduce the therapeutic (e.g., antineoplastic or antirheumatic) effect of these medicines; concurrent use should be supervised by a physician.
• Chloramphenicol: May blunt the hematologic response to vitamin B12 therapy; use with caution if a B12-deficiency anemia is being treated.
• Metformin, proton pump inhibitors, and H2-blockers: Long-term use may reduce vitamin B12 absorption, which can be a reason for supplementation with this product rather than a safety concern, but should be discussed with a physician.

Vgard is generally well tolerated at standard supplemental doses. Reported side effects include:

• Mild nausea, stomach upset, or diarrhea
• Headache
• Itching or transient skin rash
• Allergic sensitization (rare)
• Peripheral sensory neuropathy (tingling, numbness) — associated specifically with high-dose or prolonged pyridoxine (B6) use; see Precautions and Warnings.
• Mild sleep disturbance or drowsiness (uncommon)

Most side effects are mild and resolve with dose reduction or discontinuation; seek medical advice if symptoms are severe or persistent.

Vgard contains vitamins that are generally recognized as important during pregnancy and lactation at recommended dietary allowance levels, and folic acid in particular is routinely recommended to reduce the risk of neural tube defects. However, this combination product should be used during pregnancy and breastfeeding only if clearly needed and as directed by a physician, since doses in combination products may exceed standard prenatal requirements. Pregnant and breastfeeding women should consult a physician before use, particularly regarding the appropriate dose of the pyridoxine (B6) component, and should generally use dedicated prenatal vitamin formulations unless a physician specifically recommends this product.

The following precautions apply to Vgard:

• Pyridoxine (B6) neuropathy risk: High-dose or prolonged use of vitamin B6 can cause peripheral sensory neuropathy, which may be irreversible in some cases. Do not exceed the recommended dose without medical supervision.
• Masking of B12 deficiency: Folic acid supplementation can correct the megaloblastic anemia caused by vitamin B12 deficiency without correcting the underlying neurological damage, which may progress silently. This combination product is formulated to reduce this risk by including B12, but any unexplained anemia should still be properly investigated before starting supplementation, especially in older adults or those with malabsorption risk factors (e.g., pernicious anemia, bariatric surgery, chronic gastritis).
• Not a substitute for diagnosis: This product does not replace proper medical evaluation of the underlying cause of a vitamin deficiency.
• Use in seizure disorders: Folic acid may reduce the effectiveness of certain anticonvulsant medications; patients with epilepsy should use this product under medical supervision (see Interactions).

Overdose with standard multivitamin-strength Vgard products is uncommon, but very high or chronic excessive intake of the pyridoxine (B6) component can cause significant peripheral sensory neuropathy, and very high folic acid intake may mask underlying B12 deficiency. If overdose is suspected, or if numbness, tingling, or difficulty walking develops, seek immediate medical attention or contact a poison control center. Do not attempt to self-treat a suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Older adults are at increased risk of vitamin B12 deficiency due to reduced gastric acid production and intrinsic factor; Vgard may be particularly useful in this group but any underlying anemia should be properly investigated first.

Renal impairment: Use with caution; avoid high-dose pyridoxine supplementation, as impaired clearance may increase the risk of neuropathy. Consult a physician for appropriate dosing.

Hepatic impairment: No specific dose adjustment is well established; use as directed by a physician.

Patients with seizure disorders: Use with caution due to a potential interaction between folic acid and certain anticonvulsants (see Interactions).

Duration of treatment with Vgard depends on the underlying indication and response to therapy. For confirmed deficiency, treatment is typically continued for several weeks to months until vitamin levels and any associated symptoms (e.g., anemia, neuropathy) normalize, as guided by a physician and, where appropriate, follow-up laboratory testing. For general supplementation in at-risk individuals, longer-term or ongoing use may be appropriate under medical guidance.

Vitamin B-complex combination; water-soluble vitamin supplement; hematinic.

Vitamin B6, B9 and B12 acts through the combined coenzyme functions of its three component vitamins: pyridoxal-5-phosphate (from B6) supports amino acid and neurotransmitter metabolism; tetrahydrofolate (from folic acid) supports nucleic acid synthesis and cell division; and methylcobalamin/adenosylcobalamin (from B12) supports remethylation of homocysteine to methionine and normal myelin synthesis. Adequate levels of all three vitamins are required for efficient one-carbon metabolism, red blood cell maturation, and nervous system health.

Safety and efficacy of this specific fixed-dose combination have not been formally established in children. Folic acid, pyridoxine, and vitamin B12 are each used in children for confirmed deficiency states or specific medical indications, but dosing in pediatric patients should be individualized by a physician based on age, weight, and clinical indication, generally using single-vitamin or age-appropriate pediatric formulations rather than adult combination products. Vgard combination products are generally not recommended for infants and young children unless specifically directed by a pediatrician.